TLSA: Tiziana Life Sciences Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Clinical trial readouts
3 Phase 2 or 3 trials by Tiziana Life Sciences Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-09 (est.) | Foralumab | Secondary Progressive Multiple Sclerosis | Phase 2 | 54 | Enrollment complete | NCT06292923 |
| 2027-04-01 (est.) | Foralumab Nasal | Multiple System Atrophy | Phase 2 | 5 | Recruiting | NCT06868628 |
| 2027-07 (est.) | Foralumab Nasal | ALS (Amyotrophic Lateral Sclerosis) | Phase 2 | 44 | Enrolling by invitation | NCT07688239 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.